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Abstract 
Urinary incontinence is defined as involuntary leakage of any amount of urine that negatively affects 
the individual's hygienic and social status. It is an important public health problem because it has a 
high prevalence and incidence. Due to various social prejudices, it is often neglected and unreported. 
It is also characterized by its chronic appearance and complications such as decreased quality of life, 
sexual dysfunction and symptoms of anxiety and depression. The financial burden for symptomatic, 
conservative and surgical treatment of urinary incontinence is high. Both women and men are 
reluctant to seek medical help, and they most often use coping strategies to deal with urinary 
incontinence symptoms, which include the use of incontinence aids such as adult diapers and pads.  
We conducted a systematic review of high-quality randomized controlled studies and of other 
review articles to compare circumstances surrounding the diagnostic evaluation and first-line 
treatment of urinary incontinence in women and men according to International Continence Society 
guidelines. Because urinary incontinence can occur during any stage of life, diagnostic and 
therapeutic approach is different in women and men. Social stigmatization created due to urinary 
incontinence may harm a person’s self-confidence and cause many negativities at a social level.  
Timely recognition of the type and severity of symptoms of urinary incontinence is necessary to 
reduce the occurrence of the aforementioned complications.  
(Radoja I, Degmečić* D. Urinary Incontinence: Diagnostic Evaluation and First-Line Treatment. 
SEEMEDJ 2020; 4(1); 63-73) 
 
SEEMEDJ 2020, VOL 4, NO. 1 Management of Urinary Incontinence 
64 Southeastern European Medical Journal, 2020; 4(1) 
 
Introduction 
The International Continence Society (ICS) has 
defined new terminology for lower urinary tract 
symptoms (LUTS), clinical signs and conditions. 
LUTS is now divided into symptoms occurring 
during storage of urine within the bladder 
(incontinence of urine, urgency, nocturia, 
nocturnal enuresis, overactive bladder 
syndrome, increased frequency of urination, 
nocturnal polyuria), symptoms during 
micturition (dysuria, abnormalities of urine flow) 
and symptoms after urination (feeling of 
incomplete bladder emptying, dripping of urine 
after urination) (1). The most common LUTS 
occurring in women is urinary incontinence (UI) 
and the most common LUTS in both sexes is 
overactive bladder syndrome (OAB). UI is a 
symptom of involuntary leakage of urine 
subjectively reported by patients, or a clinical 
sign of involuntary leakage of urine objectively 
established by a physician (1). The amount of 
involuntary leakage of urine considered 
abnormal has not yet been defined, nor has the 
impact of UI on the psychological, physical and 
social functioning of the patient. The new 
definition specifies that UI is not a disease, but a 
symptom or clinical sign occurring due to 
various diseases of the neurological system, 
lower urinary tract, and muscles of the pelvic 
floor. Diseases that can cause the onset of UI can 
be temporary and permanent, neurogenic or 
non-neurogenic (3). UI can manifest as an 
occasional involuntary leakage of a small 
amount urine or as the complete inability to 
retain urine within the bladder. 
Given the complex aetiology of UI and the 
situations in which it occurs, UI is divided into 
several types. According to the ICS, the most 
common types of UI are stress urinary 
incontinence (SUI), urgency urinary incontinence 
(UUI) and mixed urinary incontinence (MUI) (1). 
SUI is defined as involuntary leakage of urine 
during coughing, sneezing or another physical 
activity. It is most common in women, but it is 
also present in some men who underwent 
prostate cancer surgery. UUI is defined as the 
observation of involuntary leakage from the 
urethral orifice associated with the individual 
reporting of the sensation of a sudden, 
compelling desire to void. Unlike SUI, this type 
of incontinence is unpredictable, it can happen 
at any time and it is independent of physical 
activity and bladder fullness. MUI is 
characterized by an involuntary loss of urine 
associated with urgency and also on effort or 
physical exertion, including sporting activities, or 
on sneezing or coughing. Other types of UI 
include postural UI, nocturnal enuresis, 
continuous UI, insensible UI and coital UI (4). UI 
is generally caused by the failure of pelvic floor 
muscles, the inability of the internal and external 
sphincter to withstand increased urinary bladder 
and abdominal pressure occurring during daily 
activities, or it can be a result of involuntary 
contractions of the bladder detrusor muscle. In 
most cases, women and men postpone seeking 
help from primary care health professionals. 
Usually, this is because they believe that this is a 
normal condition occurring due to pregnancy 
and vaginal delivery in women, due to an 
enlarged prostate and complications of prostate 
surgery in men, or due to older age in both 
women and men. Another reason is because 
they are not familiar with modern treatment 
possibilities. 
Prevalence and etiology of urinary 
incontinence 
UI is estimated to affect more than 450 million 
people worldwide and is three times more 
common in women than in men, regardless of 
the type of UI (5). In the total adult population of 
both sexes in the United States of America 
(USA), the prevalence of UI ranges from 5% to 
50%. UI can occur at any age, but the prevalence 
increases with age and affects approximately 
40% of older women and approximately 15% of 
older men (6). Currently, there are no data on the 
prevalence and incidence of UI in Croatia, but it 
is probably similar to those from the USA. 
According to the latest research, the prevalence 
of UI in women and men of all ages, ranges from 
20 to 50%, and the incidence of UI ranges from 
15 to 30% (7). The prevalence of UI increases with 
age and, therefore, amounts to 38% in patients 
over 60 years of age (8). The public health 
impact of UI is very high because the proportion 
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of older adults in the total population of the USA 
and other developed Western countries is 
increasing. According to recent scientific 
studies, SUI is the most common type of UI, with 
prevalence ranging from 10 to 39% (9). MUI is the 
next most common type of UI with a prevalence 
of 7% to 25% (10). UUI occurs very rarely with a 
prevalence of 1% to 7% (10). UUI occurs more 
frequently as part of OAB. OAB is defined as 
urinary urgency, usually accompanied by 
increased urination frequency during the day 
and increased urination frequency during sleep 
(i.e. nocturia), with or without UUI, and in the 
absence of a urinary tract infection or another 
obvious disease of the urinary bladder (e.g. 
bladder cancer) (4). OAB is often of idiopathic 
genesis or a consequence of a neurological 
disease, associated with excessive activity of the 
bladder detrusor muscle. The prevalence of 
OAB ranges from 2% to 53% (11). Normal total 
capacity of an adult bladder is approximately 
400 to 500ml of urine. During the day, 
approximately 1400 ml of urine is produced, 
depending on the type and volume of the fluids 
we drink. The frequency of voiding is usually 2 to 
3 times a day, and up to 1 time during the night. 
The normal desire for micturition occurs at a 
volume of 50% of normal total bladder capacity. 
Some or most of these physiological functions 
and parameters are impaired in patients with UI, 
and are most commonly caused by the 
following: pelvic floor muscle disorders, bladder 
mucosa and detrusor muscle disorders, 
neurological diseases such as cerebrovascular 
stroke (CVS), multiple sclerosis (MS), dementia 
and Parkinson's disease (12). UI can also occur in 
patients with psychological disorders such as 
schizophrenia, depression, and anxiety, or as a 
side effect of certain psychiatric medications 
(13). UI may also be associated with the onset of 
fecal incontinence, constipation and anorectal 
pain (14). Neurological signals within multiple 
micturition centers and neural pathways (e.g. 
pontine micturition center, periaqueductal gray, 
pyramidal tracts), which control the response to 
changes in pressure within the bladder, are often 
insufficient in older age. This can result in the 
loss of voluntary and autonomous control of 
lower urinary tract functions (15). Risk factors for 
SUI in women are the number of childbirths, 
injuries to the organs and muscles of the pelvis 
during childbirth, episiotomies, children with 
high birth weight and hysterectomies (16).  
The occurrence of SUI in men is associated with 
radical prostatectomy, because of the damage 
inflicted to the neural structures, the intrinsic 
urethral sphincter, and muscles and ligaments 
of the pelvic floor (12). Indications for 
hysterectomy and prostatectomy can be various 
benign and malignant diseases of the uterus or 
prostate. Annually, there are 170,000 new cases 
of prostate cancer and 60,000 new cases of 
uterine cancer in the USA (17, 18). In case of a 
localized prostate cancer, the therapeutic 
methods of choice are a radical prostatectomy 
or primary radiotherapy with curative intent. 
Depending on the surgical method, experience, 
and skill of the surgeon, the incidence of UI after 
a radical prostatectomy can range up to 40% (19). 
In most cases, these men have SUI, but they can 
also have MUI with a previously unrecognized 
UUI component (20). Occurrence of UUI or MUI 
is very common in men and women after they 
undergo primary radiotherapy for prostate and 
uterine cancer. This is because the bladder 
mucosa is damaged by irradiation and becomes 
sensitive to changes in the volume and chemical 
composition of urine. 
The pathophysiology of SUI includes damaged 
or weakened internal urethral sphincter of the 
bladder neck and pelvic floor muscles that 
support the bladder neck and urethra (16). Pelvic 
floor muscles are composed of deep and 
superficial muscle fibers and connective fibers. 
They participate in a very complex anatomical 
and physiological relationship that maintains 
maximum urethral closure pressure in order to 
prevent leakage of urine. The relaxed bladder 
neck and pelvic floor muscles allow the bladder 
to empty. In women, the maximum urethral 
closure pressure and functional urethral length 
decrease with age. Mechanisms that cause 
incontinence in older men are detrusor 
overactivity and internal sphincter insufficiency. 
In both sexes, bladder capacity and compliance 
decrease with age, while excessive contractions 
of the bladder detrusor and residual urine 
simultaneously increase, which may cause UI 
(21). Increased body mass index (BMI), family 
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history of UI and older age are also associated 
with the onset of UI (22). As abdominal and 
bladder pressure increase, the pelvic floor 
muscles cannot tighten sufficiently enough to 
hold the urine within the bladder, and, therefore, 
the intravesical pressure overcomes the 
maximum urethral closure pressure resulting in 
urine leakage.  
Neurological diseases such as dementia, CVS 
and MS, and bladder diseases such as chronic 
cystitis and cystocele, can all cause excessive 
detrusor contractions with consequent UUI or 
hypermobility of the bladder neck and urethra 
with consequent SUI (23). The prevalence of 
dementia in European countries ranges from 6 
to 18% in people over 65, and from 30 to 50% in 
people over 85 (24, 25). In Croatia, approximately 
250 people per 100,000 inhabitants experience 
CVS annually (26). The prevalence of patients 
with MS in Croatia is 143 patients per 100,000 
inhabitants (27). Some scientific studies predict 
an increase in the total number of CVS cases by 
as much as 34% in European countries in the 
period from 2015 to 2035, and they also predict 
an increase in the number of CVS survivors (28). 
The prevalence of Parkinson's disease in the US 
is 572 patients per 100,000 inhabitants (29). CVS 
and Parkinson's disease are more common in 
men, while dementia and MS are more common 
in women (30). 
Diagnostic evaluation of urinary 
incontinence 
In Croatia, family physicians and gynecologists 
play a leading role in the early identification of UI 
in primary care. Basic diagnostic methods that 
can be implemented within primary care include 
medical history, bladder diary, urinalysis, plain 
radiography and ultrasonography of the urinary 
tract with a focus on post-void residual (PVR) 
urine. After a primary care assessment, women 
are referred to a urogynecologist and men are 
referred to a urologist. Diagnostic evaluation of 
LUTS in urological and urogynaecological 
outpatient clinics includes detailed specific 
medical and sexual history, bladder diary, 
neurologic examination, prostate and genital 
examination in men, gynecological examination 
in women, and urethrocystoscopy. The causes 
of UI are obvious only in uncomplicated cases 
and a subsequently provided diagnosis is 
usually based on anamnestic data and a clinical 
examination. Some cases, however, are very 
complex and, therefore, a thorough and 
extensive assessment of UI symptoms is 
required in order to provide a correct diagnosis 
and initiate appropriate treatment. During the 
evaluation, it is useful to perform a urinalysis, a 
urine culture test and a urethrocystoscopy. 
Urinalysis and urine culture tests can detect 
urinary tract infections, hematuria, glycosuria, 
pyuria, crystalluria, and proteinuria. 
Urethrocystoscopy is mandatory because it can 
confirm or exclude diseases such as bladder 
cancer or urolithiasis. If necessary, it is advisable 
to refer women and men with UI to a 
neurourology and urodynamics specialist for 
further diagnostic evaluation and treatment. 
Urodynamics is defined as the measurement of 
physiological parameters relevant to the 
function of the lower urinary tract (1). 
Urodynamics in women and men commonly 
involves uroflowmetry with a full bladder, but 
without a catheter, measurement of PVR, filling 
cystometry, a urethral pressure profile and 
pressure-flow studies (31). In complicated cases, 
such as post-prostatectomy incontinence and 
complications of transvaginal mesh surgery, a 
videourodynamic investigation with 
simultaneous measurement of urodynamic 
parameters must be performed, along with a 
radioscopy of the bladder filled with contrast 
medium in order to gain insight into the storage 
and micturition phase. 
Sometimes it is difficult to explain the 
pathophysiology of LUTS only by correlating the 
patient's symptoms with the results of the 
urodynamic studies. Additional diagnostic tools 
may include computed tomography (CT) of the 
upper and lower urinary tract, and magnetic 
resonance imaging (MRI) of the brain and spinal 
cord for purposes of detecting tumors, 
aneurysms, injuries or other conditions. CT and 
MRI can also be used to monitor the activity and 
progression of the disease that caused the UI. 
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Treatment of urinary incontinence 
Women and men are reluctant to seek 
professional help and talk about UI problems 
and related disorders such as sexual 
dysfunction, anxiety and depression. UI can 
cause a decrease in social interactions and 
physical activity, loss of self-esteem, 
depression, fear of involuntary leakage in 
society, avoidance of sexual relations and 
decreased productivity at work. In most cases, 
patients postpone going to the physician 
because they are not fully aware of the 
treatment options for UI, which can be very 
successful.  
As first-line treatment, physicians most 
commonly use various incontinence aids and 
strategies to cope with UI problems such as 
changing their lifestyle. If incontinence aids are 
not sufficiently effective, patients need to 
change multiple pieces of the same type of aid 
or combine different types of aids during a 24-
hour period. Because of this, the costs of UI 
treatment and the financial burden on the 
healthcare system may be increased and the 
quality of life (QOL) may be significantly 
reduced. In older women and men, the 
problems and costs of UI treatment are 
increasing. The world's fastest-growing elderly 
population includes persons aged 85 and over, 
and it will increase by as much as 12 times by 
2025, while the number of people aged 100 and 
older will increase 15 times, i.e. from the current 
210,000 to 3.2 million (32). In Croatia, in 2001, 
there were 693,540 people older than 65 and 
42,553 people older than 85 (33). Depending on 
the underlying disease causing the UI and 
depending on the types of UI treatment, there 
are predictable costs of treatment (e.g. 
medication, surgery, and hospital stay costs) and 
unpredictable treatment costs (e.g. treatment of 
adverse drug effects and possible complications 
of surgery). Larger share (50-75%) of UI 
treatment costs is attributed to body care 
products, laundry detergents, incontinence 
pads and diapers (34). The total annual cost of UI 
treatment in the US is very high and in 2000 it 
was estimated at 19.5 billion dollars (35, 36). The 
most recent estimate of total annual cost of UI 
treatment in the USA for all age groups was over 
16 billion dollars, which is higher than the annual 
direct cost of treating breast, ovarian, and 
cervical cancers altogether (37, 38). According to 
one study, a person with more severe UI 
symptoms and a greater impact of UI on QOL 
spends approximately 900 dollars annually for 
incontinence aids and body care products (39). 
Another study found that the daily use of UI aids 
of one person with symptoms of UI results in an 
annual cost of 1825 dollars (approximately 150 
dollars per month) (39). These differences may 
stem from the type and effectiveness of 
incontinence aids, primarily in terms of their 
power to absorb urine. The cost of treating one 
patient with UUI or MUI with antimuscarinic 
drugs alone, without absorbents, ranges from 95 
to 290 dollars per month, depending on the type 
of drug (40). There are no data on the costs of 
treating UI in Croatia, but we can assume that 
they are very similar to the previously mentioned 
data.  
In case of contraindications for surgery or 
pharmacotherapy, a symptomatic treatment 
that includes only incontinence aids that have a 
good overall effect can reduce treatment costs 
and improve the QOL. Depending on the type of 
UI, the choice of first-line treatment includes 
conservative methods such as: counselling 
about lifestyle changes (e.g. weight control, 
avoiding or reducing intake of alcoholic and 
other diuretic drinks, reducing fluid intake during 
the day and before bedtime), bladder training 
(keeping a bladder diary, delaying the need to 
urinate, increasing the amount of time between 
urination), use of incontinence aids (e.g. pads, 
diapers), pharmacotherapy (e.g. antimuscarinics, 
mirabegron), pelvic floor muscle exercises, 
biofeedback, extracorporeal magnetic 
innervation therapy and functional 
electrostimulation of pelvic floor muscles. 
Treatment results of most conservative 
methods depend on the patient's motivation and 
co-operation, except in the case of incontinence 
aids, such as diapers and pads, where treatment 
results depend on the absorption capacity and 
comfort. Treatment of SUI focuses on 
strengthening the supportive pelvic floor 
muscles by applying various conservative and 
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surgical methods. The method of choice in UUI 
treatment is the stabilization of detrusor 
overactivity by using pharmacotherapy. In the 
case of MUI, it is necessary to treat the 
predominant symptomatology component. The 
most common surgical methods for SUI 
treatment are the periurethral injection of 
bulking agents, insertion of pubovaginal slings 
and colposuspension. If pharmacotherapy 
proves to be inefficient in treating UUI, either 
intravesical application of Onabotulinum toxin A 
or a sacral neuromodulation is indicated. All of 
the above-mentioned surgical methods include 
higher costs when compared to conservative 
methods, and they also include treatment of 
complications and a number of days spent in the 
hospital. Treatment of these complications may 
include the use of incontinence aids. Some 
patients have absolute and relative 
contraindications and an increased risk of 
complications related to conservative and 
surgical treatments that are otherwise 
recommended according to the guidelines of 
the European Association of Urology (EAU) and 
ICS (41). These include diseases such as a 
recently experienced heart attack, blood 
clotting disorders, uncontrolled arterial 
hypertension, heart rhythm disturbances, the 
presence of metal implants and heart rhythm 
electro-stimulators, and glaucoma. These 
patients can be recommended to use 
incontinence aids, make lifestyle changes, train 
their bladder, and do pelvic floor muscle 
exercises as part of the prescribed therapeutic 
method in order to help maximize the 
therapeutic effect. Incontinence aids can also 
improve the QOL of patients until a proper 
diagnosis of LUTS is made and treatment 
initiated. They can also be a permanent solution 
for patients who have an increased risk of 
developing complications during the 
implementation of diagnostic and therapeutic 
methods related to UI.  
Achieving effective and discreet urinary 
retention with the use of incontinence aids is one 
of their most important features and it helps 
improve the users’ QOL (42). The most common 
products used for UI symptoms in men and 
women are incontinence pads and diapers. They 
absorb urine after one or more episodes of 
involuntary urine leakage, depending on their 
power of absorption. These products protect 
against leakage, odour, and prevent moisture 
from getting onto the genital area and skin. 
Other products that can be used with UI patients 
include waterproof bed sheets and urinary 
condoms. Waterproof bed sheets can be 
washed in the washing machine and reused, but 
they can also be disposable. They are placed 
under normal bed sheets and above the 
mattresses, and they absorb urine. Incontinence 
pads and diapers have a hydrophobic layer that 
absorbs urine below the surface, allowing the 
genital skin to remain dry. They are usually a 
temporary measure for improving the QOL, as 
they provide safety and confidence during the 
day and help maintain a normal social life. 
Tampons are not recommended for use in 
women with UI, but they can be useful in 
situations, such as exercise, as their position can 
affect bladder neck lifting. This is due to the very 
close anatomical relationship of the vagina and 
bladder neck. Menstrual pads should also be 
avoided when dealing with UI issues. A lot of 
women use menstrual pads instead of 
incontinence pads. However, they do not have 
the same technology and, therefore, these pads 
remain wet and can cause chronic skin changes, 
contact dermatitis, and fungal infections. In 
patients experiencing involuntary leakage of 
smaller amounts of urine, incontinence pads are 
more comfortable to wear. In patients 
experiencing involuntary leakage of moderate 
to large amounts of urine, which occur several 
times a day, it is usually necessary to use diapers 
with a greater absorption capacity, in 
comparison to that of incontinence pads, or use 
a combination of both types of supplies. For 
practical reasons, mostly due to their shape and 
size, incontinence pads are mostly used by 
mobile patients who can go to the toilet on their 
own. Unlike diapers, pads are more discreet as 
they are not noticeable under clothing and are 
easy to put on and remove. In most cases, 
diapers are used by immobile patients, with or 
without cognitive impairment, who cannot go to 
the toilet on their own and who do not need to 
change supplies frequently. Diapers can absorb 
greater amounts of urine, but because they 
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need to be fixated with adhesive tapes, they are 
not practical for removing and repositioning 
during bladder training or for personal hygiene 
related reasons. Incontinence pads are more 
convenient to remove and reuse during bladder 
training, but they do not have the same 
absorption power as diapers, meaning that more 
incontinence pads need to be used during the 
day. 
Discussion 
According to EAU guidelines and World Health 
Organisation Guidelines on Integrated Care for 
Older People (WHO ICOPE), first-line of 
treatment for UI symptoms includes lifestyle 
changes, bladder training, pelvic floor exercises 
and incontinence aids (43-45). With the help of 
incontinence aids, it is possible to prevent 
involuntary leakage on clothing, eliminate the 
unpleasant odour of urine and reduce the 
possibility of bacterial infections and chronic 
dermatitis on the mucous membrane and skin of 
the genital region. The use of these aids is very 
important in patients who cannot undergo active 
treatment by other conservative or surgical 
methods due to contraindications, and in 
patients who refuse active treatment. It should 
be noted that, in most cases, these aids are used 
in patients who have UUI or MUI with a 
predominant UUI component due to the 
different aetiology of these types of UI. Because 
the onset of SUI symptoms is predictable, 
various behavioural strategies, such as bladder 
emptying before a physical activity, can help 
avoid episodes of involuntary urine leakage, and, 
consequently, the use of these aids is minimized. 
UUI is unpredictable because an overactivity of 
the bladder detrusor can occur at any time and, 
therefore, implementing similar strategies does 
not have a positive effect. One of the strategies 
used by patients with UUI is the mapping of 
toilets, meaning that they keep a record on the 
locations of toilets in a city, shopping centres, 
and public institutions. UUI patients are advised 
to change their lifestyle, train their bladder and 
use incontinence aids.  
Pharmacotherapy with antimuscarinic and beta-
agonist mirabegron is also indicated as first-line 
therapy in patients with UUI. Some patients may 
have contraindications for pharmacotherapy. 
Contraindications to antimuscarinic 
pharmacotherapy include acute or chronic 
urinary retention, digestive system diseases (e.g. 
toxic megacolon), myasthenia gravis, narrow-
angle glaucoma, renal failure requiring 
haemodialysis and severe impairment of liver 
functions. Contraindications for 
pharmacotherapy with mirabegron include 
severe uncontrolled hypertension, defined as 
systolic blood pressure ≥ 180 mmHg and 
diastolic blood pressure ≥ 110 mmHg. If there are 
any contraindications for pharmacotherapy, 
patients will be provided with incontinence aids. 
They will also have to change their habits, train 
their bladder, and implement other behavioural 
strategies.  
The prevalence of neurological diseases and 
malignant diseases of the genitourinary system 
is high, and they usually include UI as a 
consequence. Thanks to modern diagnostic and 
therapeutic options, the QOL of these patients 
has greatly improved and their life prolonged. As 
a result, there are more and more patients with 
some degree of disability and symptoms of UI. 
In these patients, a specific approach to 
treatment and rehabilitation is required in order 
to maintain their cognitive and motor skills and 
help them control the UI symptoms. 
Neurological diseases can cause immobility or 
impaired mobility, depending on their degree 
and the level of neurological damage, and this 
can cause complications such as deep vein 
thrombosis and decubital ulcers (44). Bladder 
function in these patients is often neglected, as 
is the fact that they often have symptoms of UI. 
It is very important that verticalization and 
mobility of these patients be restored in a timely 
manner through daily bladder training. It is also 
important to restore their bladder capacity and 
increase the muscle strength of detrusors, and 
also to prevent other complications. If patients 
are immobile and spend most of their 24 hours 
in a supine or sitting position, the sensory and 
motor functions of the bladder may deteriorate. 
When training the bladder, patients are advised 
to urinate during the day while retaining urine to 
a certain extent before going to the toilet.  
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If patients have UI, they must use certain types 
of aids that will hold the urine until they go to the 
toilet. Diapers would be the most appropriate 
choice because they have a greater capacity to 
absorb urine in comparison to incontinence 
pads. A negative feature of diapers is that they 
are not as discreet as pads, because they are 
larger and noticeable under clothing. This can 
cause fear of an unpleasant odour of urine, 
social prejudice, anxiety, depression, decreased 
QOL and social stigmatization (45). Incontinence 
pads are more discreet than diapers, but 
because of their lower absorption capacity, 
patients usually change up to 7 pads a day (45). 
This inflicts a huge financial burden on the health 
system. UI aids of an adequate type and size are 
required in order to prevent the detection of UI 
symptoms in social situations. This is achieved 
by reducing the absorption effect of episodes 
and the volume of involuntary leakage of urine 
during 24 hours. In addition, they also help 
reduce the possibility of complications, such as 
skin and genital mucosal damage. All patients 
with UI use some kind of an incontinence aid, 
regardless of the type and severity of UI 
symptoms. There are significant differences in 
design, absorption capabilities and other 
features between UI aids. There are also  
significant individual differences in personal 
attitudes of patients with UI and in their desires 
for incontinence treatment. Some aids are better 
designed for men than for women, for example, 
some aids have better absorption capabilities. 
Depending on the type and duration of physical 
and social activities, UI patients usually combine 
several types of aids and use multiple pieces of 
aids, especially incontinence pads, over a 24-
hourperiod. Reducing the financial burden on 
the healthcare system could be achieved by 
providing patients with better-designed UI aids 
suitable for different circumstances and 
activities for 24-hour periods. With the help of 
these conservative first-line treatment methods, 
patients can maintain an active lifestyle and 
improve sexual function and their QOL (46, 47). 
UI is a multidisciplinary problem and all 
physicians involved in the care of people with UI 
need to be well informed about the new 
scientific research data regarding diagnosing 
and treating of UI, as well as of other LUTS. 
Conclusion 
With the help of primary prevention measures, 
women and men should be educated and 
encouraged to seek help from a family 
physician, gynaecologist or urologist if they have 
UI symptoms. After reviewing the patient's 
medical history, and performing a physical 
exam, these healthcare professionals can 
determine the type of UI and begin appropriate 
treatment, if possible. A three-day bladder diary 
and various screening questionnaires, such as 
International Consultation of Incontinence 
Questionnaire – Short Form and King's Health 
Questionnaire, are useful in the evaluation of the 
type and severity of UI symptoms. Sometimes it 
is very difficult to identify the type of UI and it is, 
therefore, necessary to refer the patient to a 
neurourologist for a urodynamic assessment. 
There are many conservative and surgical 
treatment methods for UI. In most patients, we 
can achieve full continence status or a major 
improvement in alleviating UI symptoms so that 
a normal lifestyle can be maintained. There are 
many aids that can be prescribed to patients 
who have symptoms of UI, such as incontinence 
pads and diapers, which have different urine 
absorption properties. UI aids can improve the 
QOL until proper treatment is initiated, or they 
can be a permanent solution in patients with 
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